Antimicrobial Resistance in Gram-negative bacteria from Urinary Specimens: a study of prevalence, risk factors and molecular mechanisms of resistance (ARGUS) in Zimbabwe - a study protocol. by Olaru, Ioana D et al.
STUDY PROTOCOL
Antimicrobial Resistance in Gram-negative bacteria from U
rinary Specimens: a study of prevalence, risk factors and 
molecular mechanisms of resistance (ARGUS) in Zimbabwe – a 
study protocol [version 1; peer review: 2 approved]
Ioana D. Olaru 1,2, Shunmay Yeung1, Rashida A. Ferrand1,2, Richard Stabler 1, 
Prosper Chonzi3, David Mabey1, Heidi Hopkins1, John Bradley1, 
Kudzai P.E. Masunda3, Shungu Munyati2, Katharina Kranzer1,2
1Clinical Research Department, London School of Hygiene & Tropical Medicine, London, WC1E 7HT, UK 
2Biomedical Research and Training Institute, Harare, Zimbabwe 
3Department of Health, Harare City Council, Harare, Zimbabwe 
First published: 12 Jun 2020, 5:140  
https://doi.org/10.12688/wellcomeopenres.15977.1




Antimicrobial resistance (AMR) is compromising our ability to 
successfully treat infections. There are few data on gram-negative 
AMR prevalence in sub-Saharan Africa especially from the outpatient 
setting. This study aims to investigate the prevalence of and 
underlying molecular mechanisms for AMR in gram-negative bacilli 
causing urinary tract infections (UTIs) in Zimbabwe. Risk factors for 
AMR and how AMR impacts on clinical outcomes will also be 
investigated. 
Adults presenting with UTI symptoms at primary health clinics in 
Harare will be included. A questionnaire will be administered, and 
urine samples will be collected for culture. Participants with positive 
urine cultures will be followed up at 7-14 days post-enrolment. All 
participants will also be followed by telephone at 28 days to determine 
clinical outcomes. 
Bacterial identification and antibiotic susceptibility testing will be 
performed on positive cultures. 
The results from this study will be used to inform policy and 
development of treatment recommendations. Whole genome 
sequencing results will provide a better understanding of the 
prevalent resistance genes in Zimbabwe, of the spread of successful 
clones, and potentially will contribute to developing strategies to 
tackle AMR.
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Introduction
Antimicrobials have revolutionized modern medicine leading 
to important reductions in mortality, morbidity and disability. 
Their discovery and use in medical practice was, however, 
accompanied by the rapid development of resistance1. Antimicro-
bial resistance (AMR) can reverse the benefits brought by these 
drugs, leading to increased patient deaths and healthcare costs2,3. 
Considering the current trends of increasing AMR, it is esti-
mated that by 2050, 10 million deaths per year globally will be 
caused by antimicrobial resistant infections, exceeding the 
number of deaths due to cancer4.
The increase in AMR is mainly driven by inappropriate 
antimicrobial use in humans and animals and insufficient infec-
tion control systems. Exposure to antimicrobials selects for spon-
taneous mutations or the acquisition and propagation of bacterial 
clones harbouring resistance genes5. Resistance genes are then 
mobilized and can disseminate to other commensal and patho-
genic organisms6. This in turn may lead to increased carriage of 
resistant organisms in the population and an increase in use of 
second-line antimicrobial drugs7. At an individual level, other 
risk factors for infections due to resistant organisms are 
underlying co-morbid conditions and healthcare contact8.
AMR is a global problem affecting all countries irrespec-
tive of income and geographical location9. However, countries 
differ widely with regards to their detection and reporting capa-
bilities. Surveillance plays a key role in understanding the 
epidemiology of AMR and informs interventions and control 
measures. Global surveillance networks, such as the Global AMR 
Surveillance System (GLASS), were established to ensure 
standardised data collection and analysis and facilitate data 
sharing regionally and globally. However, thus far few African 
countries contribute data to these networks10, and the WHO 
Africa region has limited AMR prevalence data9,11,12. GLASS 
focuses on a number of priority pathogens including Escherichia 
coli and Klebsiella pneumoniae isolated from priority specimens 
such as blood and urine13. Figure 1 and Table 1 illustrate the 
lack of data from sub-Saharan Africa on AMR in key pathogens, 
as well as the high prevalence of resistance where such data 
are available.
Due to limited availability of diagnostics, insufficient laboratory 
capacity and suboptimal funding of health care systems, in sub-
Saharan Africa infections are often treated using a “syndromic” 
approach14. Samples for microbiological investigations are 
rarely collected outside of national tuberculosis, malaria and 
Figure 1. Studies from sub-Saharan Africa and prevalence of third-generation cephalosporin resistance in E. coli and K. pneumoniae. 
Only studies describing antimicrobial resistance prevalence in isolates from blood or urine cultures are included. The numbers in the small 
boxes represent the number of isolates with a reported third-generation cephalosporin test result. The orange bars in the graphs represent 
the proportion of isolates with third-generation cephalosporin resistance for E. coli (left) and K. pneumoniae (right). The white bars represent 
the proportion of susceptible isolates. The shaded boxes at the bottom of the picture represent the number of studies according to country. 
EC: Escherichia coli; KP: Klebsiella pneumoniae. One study presented data from multiple countries and was not included on the map. This 
figure was compiled using the studies listed in Table 1.
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HIV programmes and a few academic centers. Consequently, 
there is an overuse of antimicrobials resulting from a 
“just-in-case” approach to treating infections and a lack of resist-
ance data on which to base prescribing51. This is the case of 
ceftriaxone, which is commonly prescribed to patients admit-
ted to hospitals with suspected infections52,53. The AWaRe 
classification is a framework developed by the WHO for catego-
rizing essential antimicrobials as ‘watch’, ‘access’ or ‘reserve’ 
and for guiding their prescription and usage. According to 
this classification ceftriaxone, the most widely available third- 
generation cephalosporin, is in the “watch” group and should be 
used judiciously for restricted indications54.
Third-generation cephalosporins are essential drugs for the 
treatment of severe bacterial infections. Resistance usually 
develops through the acquisition of extended-spectrum beta- 
lactamases (ESBL), which hydrolyze the beta-lactam ring ren-
dering third-generation cephalosporins ineffective55. ESBL genes 
are transferrable between different species of Enterobacte-
riaceae and also are often associated with other mechanisms that 
cause fluoroquinolone, aminoglycoside and sulphonamide 
resistance, thus leading to resistance to the main classes of 
antimicrobials used to treat Gram-negative infections56. In 
sub-Saharan Africa, access to amikacin or to carbapenems for 
treatment of third-generation cephalosporin resistant infections is 
extremely limited and cost-prohibitive57.
Over two thirds of the 37.9 million people living with HIV (PLWH) 
are in sub-Saharan Africa58. Southern Africa is particularly 
severely affected with most countries having an adult HIV prev-
alence exceeding 10%58. PLWH attend health care facilities 
frequently for scheduled and unscheduled visits, receive more 
antimicrobial prescriptions and experience more hospital 
admissions than people without HIV, and therefore may be 
at increased risk for infections with antimicrobial-resistant 
organisms59,60.
Co-trimoxazole prophylaxis has been shown to reduce mor-
tality and hospital admissions in PLWH61, and is currently 
recommended for all children and adults with advanced HIV 
or who are at risk for malaria and severe bacterial infections62. 
However, co-trimoxazole has been reported to increase car-
riage of resistant organisms in PLWH63,64. The increase in colo-
nization with resistant organisms is not limited to an increase in 
co-trimoxazole resistance but also extends to other drug classes 
including cephalosporins and fluoroquinolones65,66. For Gram- 
negative bacilli (GNB), this may be due to the co-localization 
of resistance genes on the same mobile genetic elements which 
are transferrable between bacterial species67.
Urinary tract infections (UTIs) are the most common infec-
tions caused by GNB, with an estimated incidence of 10 per 
100 person years among women68. Resistance patterns of GNB 
causing UTIs reflect the community burden of resistance with 
the added advantage that samples are easy to obtain, and process-
ing easy to standardise69. E. coli is the most common cause of 
UTIs especially in the community setting and K. pneumoniae 
the second most common70.
Protocol
Study hypotheses
This study hypothesizes that among patients presenting with 
symptoms of UTI, PLWH have a higher risk of infections with 
resistant organisms than individuals without HIV. Addition-
ally, because of the AMR prevalence in this setting, the cur-
rent first-line treatment recommendations of amoxicillin or 
norfloxacin for UTI treatment will be suboptimal in terms of 
bacterial antimicrobial susceptibility and resolution of infection.
Study aims and objectives
The aims of this study are i) to determine if infections in 
PLWH are more commonly due to antimicrobial resistant 
organisms, compared with infections in individuals without 
HIV infection; ii) to explore the prevalence of and underlying 
molecular mechanisms for AMR in GNB causing UTIs, iii) to 
investigate risk factors for AMR, and iv) to examine how AMR 
impacts on clinical outcome.
Primary objective:
1    To determine if there is an association between HIV status 
and infections with ESBL-producing E. coli in adults 
(aged 18 years or older) who present with symptoms of 
UTI to primary healthcare services in Harare, Zimbabwe.
Secondary objectives:
2    To estimate the prevalence of third-generation 
cephalosporin resistance due to ESBL production in E. coli 
isolated from individuals who present with symptoms of 
UTI to primary healthcare services in Harare;
3    To determine the prevalence of resistance to amoxicillin 
and quinolones (first-line drugs for UTIs according to 
Zimbabwean National guidelines71) in bacteria causing 
UTIs;
4    To identify the risk factors associated with UTIs with 
bacteria resistant to amoxicillin and quinolones, and with 
ESBL-producing and multidrug-resistant bacterial strains;
5    To determine the impact of resistance to first-line 
antimicrobials (amoxicillin and ciprofloxacin) on clinical 
outcomes (defined as complete resolution of symptoms 
at follow-up);
6    To evaluate the causes of negative urine cultures in this 
setting;
7    To determine the molecular mechanisms leading to 
AMR, virulence factors and population diversity of E. coli.
Methods
Study setting
The study is conducted in primary healthcare clinics (PHCs) in 
Harare, Zimbabwe. PHCs provide acute primary care, includ-
ing treatment for common infections. In addition, all PHCs 
have 1) maternity services to record and follow pregnancies 
in their catchment area and perform uncomplicated deliveries, 
2) family planning and well-child services for growth monitor-
ing and vaccinations, and 3) HIV services for regular follow-ups 
and provision of antiretroviral therapy.
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The study sites are selected based on the number of clinic pres-
entations, their catchment population and their location within 
Harare. The catchment population of the clinics, of over 800,000 
people72, belong mostly to the low-income strata and live in 
densely populated communities. The clinics selected serve the 
populations of the following suburbs: Budiriro, Glen View, 
Glen Norah, Mufakose, Highfields, Kuwadzana, Warren Park, 
Dzivarasekwa, Kambuzuma and Mbare.
The PHCs are primarily nurse-led and prescriptions are issued 
in accordance with national guidelines54. UTIs are usually 
diagnosed clinically and first-line treatment is with a fluo-
roquinolone or amoxicillin. Patients purchase antimicrobials 
according to prescription either at the PHC pharmacy or at other 
pharmacies in the community. Study-specific procedures are 
performed by the study staff who are trained on the protocol 
and relevant study procedures.
Study design
This is a prospective cohort study enrolling adults (aged 
≥18 years) who present with symptoms of UTI at PHCs in 
southwest Harare, Zimbabwe. Recruitment into the study will 
be over an 18-month period. All participants are followed up by 
telephone at 28 days post-enrolment. In addition, participants 
with a positive urine culture at enrolment are followed up 
between 7 and 14 days post-enrolment to provide a urine sample 
to assess for clearance of infection (Figure 2).
Participant recruitment
Study staff screen and enrol participants according to the eligibil-
ity criteria. Recruitment is conducted five days per week during 
regular PHC opening hours. A total of 1500 participants with 
suspected UTIs will be enrolled. The reason for exclusion of 
screened participants is recorded.
Eligibility
Patients are enrolled into the study if they fulfil all the 
inclusion criteria and do not have any of the exclusion criteria.
Inclusion criteria:
-   age ≥18 years
-    presenting with symptoms of UTI (≥2 of the following: 
dysuria, urgency, frequency, suprapubic pain and/or flank 
pain). The presence of at least two symptoms is required in 
order to exclude those who are more likely to have other 
conditions (e.g. sexually transmitted infections)
-   onset of symptoms within two weeks prior to presentation
-   presence of symptoms within the last 24 hours
-   provision of written informed consent
Exclusion criteria:
-   discharge from hospital within the previous 72 hours
-   having a urinary catheter in-situ
Individuals with catheters are excluded because they are 
likely to represent a different population with more healthcare 
exposure, and are more likely to have previously been prescribed 
antimicrobials and to have infections with resistant organisms. 
These infections are more likely to be healthcare associated 
infections rather than community acquired infections, which 
is the focus of this study. Recruiting individuals with urinary 
catheters would therefore likely lead to an over-estimation of 
community-level resistance.
Procedures at enrolment
Clinical and demographic data collection. Data on age, sex, 
socio-economic status (measured using standardised asset 
ownership tool, education and employment of the head of the 
household73), clinical history, prior health care seeking (traditional 
healer, private practitioner, pharmacy), and risk factors for AMR 
(prior antimicrobial use or hospitalization during the previous 
six months, comorbidities including HIV status, antiretroviral 
treatment, co-trimoxazole prophylaxis, chronic kidney disease 
and diabetes, current or recent pregnancy, recurrent UTIs) are 
Figure 2. Outline of procedures at enrolment and follow-up. UTI: urinary tract infection, Abx: antibiotics.
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collected using an interviewer-administered questionnaire, con-
firmed by patient-held records. Drug treatment (if any) and 
duration of treatment prescribed by the health care worker is 
recorded. Results of HIV tests, which are routinely carried out 
at the PHCs, are documented.
Sample collection and laboratory processing
A midstream urine sample for microscopy, culture and 
antimicrobial susceptibility testing (AST) is collected in a sterile 
container. The samples are transported to the laboratory as soon 
as possible and if a prolonged time to delivery is anticipated 
(>4 hours), the samples are cooled to prevent overgrowth of 
contaminants.
Urine samples undergo dipstick and microscopy for leucocytes, 
and culture. A standardised sample volume (1 µl) is inoculated 
on chromogenic agar (Brilliance UTI agar, Oxoid, UK). Pre-
sumptive bacterial identification is performed according to the 
manufacturers’ instructions. A urine culture is considered 
positive if ≥103 colony forming units (CFU)/mL are present with 
either pure culture or predominance of one organism74. If cul-
tures grow a non-uropathogen or if ≥2 organisms are isolated 
in the absence of a clear predominance of one organism, the 
culture is considered contaminated. When GNBs cannot be iden-
tified by colony appearance on chromogenic agar, biochemi-
cal testing with APIs (Analytical Profile Index, bioMérieux, 
France) is used. AST is performed using the Kirby-Bauer disc 
diffusion method and interpreted using EUCAST standards75. 
Screening for ESBL production is performed according to 
EUCAST recommendations76. Briefly, if resistance to cefpodox-
ime alone or ceftriaxone and ceftazidime is detected, double-disc 
synergy testing between a cephalosporin and clavulanic acid 
is performed. Similarly, for AmpC detection in isolates with 
cefoxitin and ceftazidime resistance, synergy testing between 
cefoxitin and cloxacillin is carried out. In addition, for iso-
lates resistant to third-generation cephalosporins, the minimum 
inhibitory concentration for ceftriaxone is determined using 
E-tests (bioMérieux, France).
All bacterial isolates are stored on storage beads at -80°C. Stored 
E. coli isolates will be used to re-establish cultures on agar plates 
from which DNA will be extracted using the DNA QIAmp 
Mini Kit (Qiagen, Hilden, Germany). E. coli isolates will undergo 
whole genome sequencing to ascertain molecular determinants 
of AMR, virulence factors and population diversity. For whole 
genome sequencing, DNA libraries will be prepared using the 
Nextera XT DNA Sample Preparation Kit (Illumina, San Diego, 
USA) as per the manufacturer’s instructions. The libraries will 
be sequenced using the Illumina HiSeq platform (Illumina, 
San Diego, USA). Trimmed reads will be assembled into 
contigs using SPAdes and using a publicly available E. coli ref-
erence genome. Antimicrobial genotype and virulence gene 
prediction will be performed using ABRicate. Phylogeny will be 
determined using FastTree and viewed in FigTree.
Evaluation of negative urine cultures
Pilot data and data from other studies from sub-Saharan 
Africa77,78 have shown that a large proportion of urine cultures 
from patients with symptoms suggestive of UTI are negative 
(60–75%) as compared to 25% in Europe79. This may be due to 
various causes such as antimicrobial use prior to sample collec-
tion, low bacterial load, delayed sample inoculation leading to 
overgrowth of contaminants or depletion of pathogen, or symp-
toms due to sexually transmitted infections rather than UTIs. 
These alternative causes will also be investigated in a subset of 
participants from this study (Figure 3).
To determine recent antimicrobial use, information on antimi-
crobials prior to clinic presentation and on co-trimoxazole use 
for HIV-positive individuals will be collected. In addition, urine 
samples will be evaluated for antimicrobial residues using a disc-
diffusion adapted from Driscoll et al.80. Low bacterial loads will 
Figure 3. Evaluation of causes for negative urine cultures. STI: sexually transmitted infections; CT: Chlamydia trachomatis; NG: Neisseria 
gonorrhoeae; TV: Trichomonas vaginalis. 
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be investigated using a highly sensitive culture system that is 
employed for testing coliform contamination of water and food 
(CompactDry EC, Nissui, Japan). Point of care inoculation 
of urine samples using InTrays (BioMed Diagnostics) will be 
used to determine if sample transportation delays may contribute 
to contamination and pathogen loss. The prevalence of sexu-
ally transmitted infections in Zimbabwe can be as high as 
15–20% (unpublished data from Ferrand R.A. et al.). A 
subset of urine samples will be tested for gonorrhoea and 
chlamydia using Xpert CT/NG (Cepheid, Sunnyvale, CA, USA) 
and for trichomonas vaginalis using Xpert TV (for women only).
Provision of routine care for study participants
Clinical care for study participants remains the responsibil-
ity of routine health care providers. Urine dipstick, microscopy 
and culture results are provided to the clinic health care work-
ers, with advice from the study physician on management for 
complicated cases (such as prior treatment failure, isolation of 
multidrug resistant bacteria, pregnancy, or severe kidney or liver 
disease requiring dose-adjustment).
Procedures at follow-up
Participants who have a positive urine culture at enrolment 
have a follow-up visit between 7 and 14 days after enrolment. 
Participants are asked to provide information on their symp-
toms, antimicrobial use and healthcare seeking since their enrol-
ment. If a participant has not taken a prescribed antimicrobial, the 
reasons are also recorded. A second urine culture is collected 
to assess for clearance. If UTI symptoms have not resolved, a 
second course of antimicrobials based on results of the AST is 
considered, as clinically appropriate.
All participants, irrespective of enrolment culture results, are 
followed up by telephone 28 days after enrolment to assess 
clinical outcomes (i.e. symptom resolution, hospital admission, 
UTI symptom recurrence).
Participants due to come to the clinic for a follow-up visit will 
be notified in advance of their appointment. If participants 
are unable to come to the clinic, a home visit will be performed. 
For the telephone follow-up visit at 28 days, participants will be 
called on at least three separate occasions on two different days. 
If they cannot be reached by telephone, a home visit will be 
attempted. Loss to follow-up will only impact on the outcome 
analysis and was accounted for in the sample size calculation.
Outcome measures
A UTI is classified as confirmed if the urine culture is positive 
with a recognised urinary pathogen or possible if the culture is 
negative or shows contamination. Bacteriological cure is defined 
as a negative urine culture following an initial positive urine 
culture. Clinical cure represents resolution of symptoms at the 
7- to 14-day follow-up. Relapse is defined as the absence of a 
positive culture and symptoms after seven days but reappear-
ance or re-presentation with symptoms within 28 days of the 
initial presentation. AMR to specific drugs and ESBL are defined 
using the EUCAST standards and guidelines for detection of 
resistance mechanisms75,81. Multidrug resistance is defined as 
resistance to one agent from at least three different antimicrobial 
classes82.
Data management
All processes related to data collection, management and stor-
age are governed by standard operating procedures (SOPs) and 
follow the principles of Good Clinical Practice.
All participants are identified throughout the study by a unique 
identifying number that is assigned at recruitment using 
uniquely numbered and barcoded consent forms. Apart from 
age and sex no personal data are collected on the clinical report 
forms.
All data are collected and entered on handheld tablets into 
pre-designed forms using the Open Data Kit (ODK, www. 
opendatakit.org) software. Electronic data entry quality is 
ensured by real-time error capture, internal validation, con-
sistency checks and stringent formatting constraints. For the 
instances when the data cannot be entered directly into the elec-
tronic form (e.g. laboratory results that are only available after 
24–49h), data are recorded onto paper forms. Upon comple-
tion of the laboratory tests, the data from the paper forms are 
entered electronically. Paper forms are available in case of 
failure of electronic data entry in the field.
Data analysis
Categorical variables will be analysed using counts and 
percentages and continuous variables using means/medians and 
standard deviations/interquartile ranges. The proportions of 
study participants with a positive, contaminated and negative 
urine culture will be determined. Prevalence and 95% confidence 
intervals will be presented for each causative organism and for 
resistance to antimicrobials. Univariate associations between 
risk factors and the presence of first-line and first- and second- 
line resistance and clinical and bacteriological outcome will be 
assessed using the χ2 test for categorical variables. STATA (version 
14, Stata-Corp, TX, USA) will be used for data analysis.
For the primary objective (association between HIV infection 
and ESBL presence in E. coli), a logistic regression model will 
be built, which will include age and sex as the pre-specified con-
founders and which will be controlled for the other variables 
which show an association in the univariate analysis (e.g. recent 
hospitalization, recent antimicrobial use, pregnancy). The molec-
ular mechanisms of resistance and virulence factors will be 
reported in a descriptive analysis.
Sample size estimates
The sample size calculations used the following assumptions 
from published studies and a pilot study: 30% of urine cultures 
are positive40,41, 90% of the positive cultures yield E. coli, 
ESBL prevalence in E. coli is 15% in HIV-negative and 30% 
in HIV-positive individuals, 25% of participants are HIV- 
positive and 90% of study participants know their HIV status. 
In order to determine if there is a difference in proportions of 
ESBL-producing E. coli between HIV-positive and HIV-negative 
individuals, 1404 participants presenting with symptoms of UTI 
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would need to be recruited into the study, of which 405 would 
be included in the primary outcome analysis.
For the clinical outcome analysis, UTI with a bacterial strain 
showing AMR (defined as resistance to ciprofloxacin or 
amoxicillin according to Zimbabwean guidelines)71 will be con-
sidered as the exposure, and complete resolution of symptoms 
(clinical cure) at the day 7 follow-up visit the outcome. Prelimi-
nary data from this study have shown that the prevalence of AMR 
in UTI isolates is 83%. The assumptions used will be: 
500 cultures are positive, loss to follow up is 10%, 80% of iso-
lates are resistant to amoxicillin or ciprofloxacin, 30% of partici-
pants with symptoms have a positive culture, and 20% of patients 
did not take antimicrobials. Estimating a positive impact of 
treatment on clinical cure in participants without AMR of 
80–90% and 40–50% in participants with AMR, the study will 
have >80% power to detect a difference between the groups.
Study status
The study began recruiting participants in June 2019 and 
recruitment is ongoing.
Discussion
Although there are indications that PLWH are at increased 
risk for infections with resistant organisms as compared to the 
general population, most studies have focused on gram-positive 
pathogens such as Streptococcus pneumoniae83 and Staphyloco-
ccus aureus84. The ARGUS study will investigate if there is an 
association between HIV infection and AMR in GNB causing 
UTIs in Harare. The study will also investigate other risk factors 
for AMR in this setting. Results may contribute to the develop-
ment of specific treatment recommendations based on the risk of 
AMR. Furthermore, the study will provide important data on the 
prevalence of AMR in community-acquired infections caused 
by GNB in this setting which will inform antibiotic prescribing 
guidelines, as well as the development of strategies to prevent 
further dissemination of resistance. The findings of this study are 
especially important since data on priority organisms for AMR 
surveillance from a large number of clinics across Harare will be 
collected. The information on outcomes of infections will 
guide the design of future management algorithms including 
identification of patients at risk for persistent infections and for 
complications.
The study is limited by its recruitment from a single city in 
Zimbabwe and therefore results might not be generalizable to 
the whole country which has a predominantly rural population. 
However, participants are recruited from ten PHCs across 
Harare and are therefore representative of the urban popula-
tion. Individuals accessing healthcare at the clinics are required 
to pay a consultation fee. Due to the economic challenges in 
Zimbabwe, there has been an increase in consultation fees 
alongside rapid inflation. Therefore, individuals with mild 
symptoms may not access the clinic and will therefore not be 
included.
Ethics and dissemination
The study was approved by the ethics committees of the 
Medical Research Council of Zimbabwe (MRCZ/A/2406), the 
London School of Hygiene and Tropical Medicine (Ref. 16424), 
and the Biomedical Research and Training Institute. The study 
was granted permission from the City of Harare Department of 
Health. All study participants have provided/must provide written 
informed consent prior to enrolment into the study.
The study results will be disseminated to healthcare workers 
at the clinics through leaflets and dissemination meetings with 
the aim to enhance understanding, discuss the findings and ulti-
mately improve future patient management. Significant micro-
biological results from individual patients will be reported 
to the attending healthcare worker as soon as they are available, 
in order to optimise treatment for individual patients. A report of 
the study results will be provided to the PHC healthcare workers, 
the Ministry of Health and Child Care, Harare City Health and 
other relevant stakeholders and policy makers. Data from this 
study may be used to inform treatment guidelines in order to 
improve patient management. The results of this study will be 
presented at national and international conferences to a wider 
audience and will be published in peer-reviewed journals.
Data availability
No data are associated with this article.
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The high rate of negative cases (60–75%) could also be due to inappropriate ordering and 
acquisition of urine cultures (Redwood et al., 2018)1. The fact that this service is free-of-




“to treat infections successfully.” instead of “to successfully treat infections.”   
 
○
“Gram-negative” instead of “gram-negative” (correct throughout the manuscript). 
 
○
to investigate the prevalence and determine the molecular mechanisms of AMR in. 
 
○
“and its impact on clinical outcomes” instead of “how AMR impacts on clinical outcomes”. 
 
○




Maybe “understanding of the molecular epidemiology of successful pathogens and the 
prevalence of clinically significant AMR genes in Zimbabwe”. 
 
○
has, however, been accompanied. ○
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Delete “At an individual level”. 
 
○
“The risk factors ...” instead of “Other risk factors …”  
 
○
Maybe re-write as: Underlying co-morbid conditions and … are major risk factors for 
infections due to resistant organisms. 
 
○
What do you mean by “healthcare contact”? Be more specific. 
 
○
However, few African countries have so far contributed data to these networks. 
 
○
health care systems in sub-Saharan Africa, infections are  
 
○
“antimicrobials as ‘access’, ‘watch’ or ‘reserve’ and for” instead of “antimicrobials as ‘watch’, 
‘access’ or ‘reserve’ and for“ 
 
○
According to this classification, … 
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“access to amikacin or carbapenems” instead of “access to amikacin or to carbapenems” 
 
○
severely affected, with most countries  
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Re-write a correctly structured sentence instead of “However, co-trimoxazole has been 
reported to increase carriage of resistant organisms in PLWH” 
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Delete “which are transferrable between bacterial species.” 
 
○
Delete “i) to determine if infections in PLWH are more commonly due to antimicrobial 
resistant organisms, compared with infections in individuals without HIV infection;” 
 
○
Re-write a clear sentence instead of “ii) to explore the prevalence of and underlying 
molecular mechanisms for AMR in GNB causing UTIs,” 
 
○
Change the order of sentences as following: Primary healthcare clinics (PHCs) in Zimbabwe 
provide acute primary care, including treatment for common infections. In addition, all 
PHCs have 1) maternity services to record and follow pregnancies in their catchment area 
and perform uncomplicated deliveries, 2) family planning and well-child services for growth 
monitoring and vaccinations, and 3) HIV services for regular follow-ups and provision of 
antiretroviral therapy. The study is conducted in “add the exact number” selected PHCs in 
Harare, Zimbabwe. The study sites are selected based on the number of clinic 
presentations, their catchment population and their location within Harare. The catchment 
population of the clinics, of over 800,000 people72, belong mostly to the low-income strata 
and live in densely populated communities. The selected “PHCs” serve the populations of 
the following suburbs: Budiriro, Glen View, Glen Norah, Mufakose, Highfields, Kuwadzana, 
Warren Park, Dzivarasekwa, Kambuzuma and Mbare. 
 
○
Delete “for microscopy, culture and antimicrobial susceptibility testing (AST)” ○
 
Page 17 of 20
Wellcome Open Research 2020, 5:140 Last updated: 12 OCT 2020
 
A UTI is classified as “confirmed” if the urine culture is positive with a recognised urinary 
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The article is well written with a very nice review of the (limited) literature on AMR in sub-Saharan 
Africa and the excellent Figure 1.  
 
The proposed study is sound and will be a very welcome addition to our understanding of AMR in 
Zimbabwe. Given the paucity of high-quality microbiological data that is representative of the 
wider community, this data will also have relevance to other low-income countries with similar 
population structures and health care provision. The opportunity to explore the high rates of 
culture-negative urines in this setting by measuring urinary antibiotics, maximising sensitivity, 




There is still some debate about the evidence base on what drives AMR - advise softening 




Introduction 4th paragraph: A major issue with existing microdata from LMIC settings is 
data quality. Advise mentioning this, and a sentence in your discussion on how the micro 
lab to be used demonstrates quality (use of EUCAST already described, can add the use of 
standard controls, plus the fact that the isolates will be sequenced. See ref (1)). You can also 
add that existing AMR data is biased towards the data from the more wealthy population 
due to more microdata coming from private labs and cities. Your community-based design 
will capture a much more representative population than most of the published literature. 
 
2. 
The data analysis plan is good. Consider including as a variable in the screening univariate 
analysis some metrics for each clinic such as clinic size and district as I imagine there will be 
heterogeneity in the types of clinics. Do all the clinics have the same funding source? How 
many clinics will be used? 
 
3. 
Very minor, but most international style guides advise using a capital G from Gram, after 
the Danish microbiologist. However, I do concede that some US journals style guides prefer 
the lower case g. 
4. 
 
Overall this is the sort of well thought-out, comprehensive study in a representative population 
that is very much needed for understanding the global burden and mechanisms of AMR. 
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